TGF-BETA IN THE NATURAL HISTORY OF PROSTATE CANCER

Overview

Journal Acta Clin Croat

Specialty General Medicine

Date 2019 Aug 1

PMID 31363335

Citations 19

Authors

Jamal Ahel

Narcis Hudorovic

Visnja Vicic-Hudorovic

Hrvoje Nikles

Affiliations

Soon will be listed here.

Abstract

All transforming growth factors beta (TGFß) are cytokines that regulate several cellular functions such as cell growth, differentiation and motility. They may also have a role in immunosuppression. Their role is important for normal prostate development. TGFß is active in the regulation of balance between epithelial cell proliferation and apoptosis through stromal epithelia the androgen receptor action. TGFß protects and maintains prostate stem cells, an important population necessary for prostate tissue regeneration. However, TGFß is shown to have a contrasting role in prostate tumor genesis. In the early stages of tumor development, TGFß acts as a tumor suppressor, whereas in the later stages, TGFß becomes a tumor promoter by inducing proliferation, invasion and metastasis. In this review, we outline complex interactions that TGFß-mediated signaling has on prostate tumor genesis, focusing on the role of these interactions during the course of prostate cancer and, in particular, during disease progression.

Citing Articles

Microphysiological systems as models for immunologically 'cold' tumors.

Gaebler D, Hachey S, Hughes C Front Cell Dev Biol. 2024; 12:1389012.

PMID: 38711620 PMC: 11070549. DOI: 10.3389/fcell.2024.1389012.

Prostate Cancer and the Mevalonate Pathway.

Guerrero-Ochoa P, Rodriguez-Zapater S, Anel A, Esteban L, Camon-Fernandez A, Espilez-Ortiz R Int J Mol Sci. 2024; 25(4).

PMID: 38396837 PMC: 10888820. DOI: 10.3390/ijms25042152.

Emerging role of transforming growth factor-β-regulated long non-coding RNAs in prostate cancer pathogenesis.

Shree B, Das K, Sharma V Cancer Pathog Ther. 2024; 1(3):195-204.

PMID: 38327834 PMC: 10846338. DOI: 10.1016/j.cpt.2022.12.003.

Recent advances and future perspectives in the therapeutics of prostate cancer.

Varaprasad G, Gupta V, Prasad K, Kim E, Tej M, Mohanty P Exp Hematol Oncol. 2023; 12(1):80.

PMID: 37740236 PMC: 10517568. DOI: 10.1186/s40164-023-00444-9.

The Lack of Standardization and Pharmacological Effect Limits the Potential Clinical Usefulness of Phytosterols in Benign Prostatic Hyperplasia.

But M, Jitca G, Imre S, Vari C, osz B, Jitca C Plants (Basel). 2023; 12(8).

PMID: 37111945 PMC: 10142909. DOI: 10.3390/plants12081722.

References

Wikstrom P, Westin P, Stattin P, Damber J, Bergh A . Early castration-induced upregulation of transforming growth factor beta1 and its receptors is associated with tumor cell apoptosis and a major decline in serum prostate-specific antigen in prostate cancer patients. Prostate. 1999; 38(4):268-77. DOI: 10.1002/(sici)1097-0045(19990301)38:4<268::aid-pros2>3.0.co;2-4. View

Wang D, Sun L, Zborowska E, WILLSON J, Gong J, Verraraghavan J . Control of type II transforming growth factor-beta receptor expression by integrin ligation. J Biol Chem. 1999; 274(18):12840-7. DOI: 10.1074/jbc.274.18.12840. View

Lee H, Timme T, Thompson T . Resistance to lysis by cytotoxic T cells: a dominant effect in metastatic mouse prostate cancer cells. Cancer Res. 2000; 60(7):1927-33. View

Blobe G, Schiemann W, Lodish H . Role of transforming growth factor beta in human disease. N Engl J Med. 2000; 342(18):1350-8. DOI: 10.1056/NEJM200005043421807. View

Rich A . Classics in oncology. On the frequency of occurrence of occult carcinoma of the prostate: Arnold Rice Rich, M.D., Journal of Urology 33:3, 1935. CA Cancer J Clin. 1979; 29(2):115-9. DOI: 10.3322/canjclin.29.2.115. View

Matthews E, Yang T, Janulis L, Goodwin S, Kundu S, Karpus W . Down-regulation of TGF-beta1 production restores immunogenicity in prostate cancer cells. Br J Cancer. 2000; 83(4):519-25. PMC: 2374659. DOI: 10.1054/bjoc.2000.1257. View

Abate-Shen C, Shen M . Molecular genetics of prostate cancer. Genes Dev. 2000; 14(19):2410-34. DOI: 10.1101/gad.819500. View

Wikstrom P, Damber J, Bergh A . Role of transforming growth factor-beta1 in prostate cancer. Microsc Res Tech. 2001; 52(4):411-9. DOI: 10.1002/1097-0029(20010215)52:4<411::AID-JEMT1026>3.0.CO;2-8. View

Stravodimos K, Constantinides C, Manousakas T, Pavlaki C, Pantazopoulos D, Giannopoulos A . Immunohistochemical expression of transforming growth factor beta 1 and nm-23 H1 antioncogene in prostate cancer: divergent correlation with clinicopathological parameters. Anticancer Res. 2001; 20(5C):3823-8. View

10.

Hayes S, Zarnegar M, Sharma M, Yang F, Peehl D, Ten Dijke P . SMAD3 represses androgen receptor-mediated transcription. Cancer Res. 2001; 61(5):2112-8. View

11.

van Leenders G, Schalken J . Stem cell differentiation within the human prostate epithelium: implications for prostate carcinogenesis. BJU Int. 2001; 88 Suppl 2:35-42; discussion 49-50. DOI: 10.1046/j.1464-410x.2001.00117.x. View

12.

Gorelik L, Flavell R . Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat Med. 2001; 7(10):1118-22. DOI: 10.1038/nm1001-1118. View

13.

Chipuk J, Cornelius S, Pultz N, Jorgensen J, Bonham M, Kim S . The androgen receptor represses transforming growth factor-beta signaling through interaction with Smad3. J Biol Chem. 2001; 277(2):1240-8. DOI: 10.1074/jbc.M108855200. View

14.

Juliano R . Signal transduction by cell adhesion receptors and the cytoskeleton: functions of integrins, cadherins, selectins, and immunoglobulin-superfamily members. Annu Rev Pharmacol Toxicol. 2002; 42:283-323. DOI: 10.1146/annurev.pharmtox.42.090401.151133. View

15.

Tsujimura A, Koikawa Y, Salm S, Takao T, Coetzee S, Moscatelli D . Proximal location of mouse prostate epithelial stem cells: a model of prostatic homeostasis. J Cell Biol. 2002; 157(7):1257-65. PMC: 2173539. DOI: 10.1083/jcb.200202067. View

16.

Chen C, Kang Y, Siegel P, Massague J . E2F4/5 and p107 as Smad cofactors linking the TGFbeta receptor to c-myc repression. Cell. 2002; 110(1):19-32. DOI: 10.1016/s0092-8674(02)00801-2. View

17.

Chambers A, Groom A, MacDonald I . Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer. 2002; 2(8):563-72. DOI: 10.1038/nrc865. View

18.

Kang H, Huang K, Chang S, Ma W, Lin W, Chang C . Differential modulation of androgen receptor-mediated transactivation by Smad3 and tumor suppressor Smad4. J Biol Chem. 2002; 277(46):43749-56. DOI: 10.1074/jbc.M205603200. View

19.

Tuxhorn J, Ayala G, Smith M, Smith V, Dang T, Rowley D . Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. Clin Cancer Res. 2002; 8(9):2912-23. View

20.

Robertson S, Ingman W, OLeary S, Sharkey D, Tremellen K . Transforming growth factor beta--a mediator of immune deviation in seminal plasma. J Reprod Immunol. 2002; 57(1-2):109-28. DOI: 10.1016/s0165-0378(02)00015-3. View